A Supply Tsunami Hits US Markets: SpaceX Lockup Unlocks $101B While $5B in Follow-Ons Price

The single most important question for US equity markets this week is not what the Fed will do, or whether Q2 earnings season delivers beats. It is whether the market can absorb the largest concentrated wave of share supply seen in years—arriving on a compressed timeline that tests the plumbing.

On Thursday, August 6, 2026, SpaceX’s first post-IPO lockup expiration unlocks approximately 911.5 million insider shares, more than doubling the free float from roughly 639 million to 1.55 billion shares and freeing stock worth an estimated $101 billion at recent prices^[1][2]. This is happening in the same week that Prologis (PLD), Celestica (CLS), and Twist Bioscience (TWST) collectively raised over $5 billion in follow-on equity offerings^[3][4][5].

The convergence is not coincidental. Issuers and their bankers read the same tape everyone else does, and August’s relatively stable index levels—following a sharp late-July reset that Citadel Securities described as “one of the most technically challenging trading environments we have navigated in recent years”^[6]—opened a window. The question is whether that window is wide enough.

The SpaceX Unlock: Unprecedented in Scale and Structure

SpaceX went public on June 12, 2026 at $135 per share, raising $85.7 billion by selling roughly 4.3% of the company^[2]. The IPO was the largest in history by deal size, and the lockup structure reflects that scale. HSBC analysts mapped out a staggered release schedule: the first tranche of approximately 912 million shares becomes sellable on August 6, with further releases contingent on price triggers—specifically, whether the stock trades above $175.50 for at least five of ten consecutive trading days^[1].

The stock has done the opposite. As of Monday, August 4, SpaceX touched a record low of $104.83, sitting 22.4% below its offering price and 53.5% beneath its June peak of $225^[1]. The selloff has erased more than $1 trillion in market value since the IPO. Short sellers have piled in: S3 Partners data through Tuesday’s close shows 35% of the free float is sold short^[1].

Elon Musk himself cannot sell a single share for 366 days post-IPO, meaning the initial selling pressure—if it materializes—will come from funds and individuals who participated in SpaceX’s private financing rounds^[2]. Whether those holders, many of whom held private positions for years, will rush for the exit is the central unknown. As Baillie Gifford’s Peter Singlehurst, who first invested in SpaceX in 2018, told Bloomberg: “We’ve never seen anything like it. We’ve never seen anything of this scale, and we’ve never seen a lockup phased in this way. We’re in uncharted waters”^[1].

The free float jumps from 4.9% of shares outstanding to 11.8% after today’s unlock^[1]. That is still a small percentage in absolute terms, but the rate of change—more than doubling tradable supply overnight—is what makes this a market-structure event rather than a routine lockup expiry.

The Follow-On Wave: $5.4 Billion in a Single Week

While SpaceX’s lockup release is involuntary supply—shares entering the sellable pool regardless of issuer intent—the follow-on wave is deliberate, issuer-driven supply. Three deals priced between August 4 and August 6, totaling over $5.4 billion:

The Prologis offering is the most strategically significant. The 15 million shares priced at $139.85 are explicitly tied to Prologis’s $18.8 billion acquisition of SEGRO, a London-based logistics warehouse operator^[7][3]. The deal is a cross-border logistics consolidation play, and the equity raise is a down payment on financing it. Prologis stock fell roughly 3% on the announcement, a modest discount that suggests the market is willing to absorb the supply—but at a price.

The Celestica deal is the most aggressively sized relative to the company’s market capitalization and drew the sharpest reaction. The $3 billion raise at $310 per share triggered an 11% after-hours decline and a 14.7% pre-market drop to $309.30 on August 6^[4]. Celestica framed the proceeds as funding its AI infrastructure buildout, but with the stock trading at $362.76 at the prior close—described by some valuation screens as more than 100% above fair-value estimates—the offering read to the market as a timing decision: sell equity while the AI-narrative premium remains intact^[4].

Twist Bioscience’s upsized $300 million offering, managed by Goldman Sachs, William Blair, Leerink Partners, and Guggenheim Securities, priced at $96.00 per share after initially being announced at $250 million^[5]. The upsizing—the second in this week’s batch, alongside Attovia’s IPO—indicates that underwriter books were well-covered at the higher size, a signal of institutional appetite for biotech growth paper even in a heavy-supply week.

The IPO Market: Attovia’s Debut and the Biotech Window

On the primary issuance side, Attovia Therapeutics (ATTO) priced its upsized IPO on August 4 at $17.00 per share—the top of its range—selling 17 million shares to raise $289 million^[8]. The deal was upsized by 45% from the original filing, and the stock rose approximately 29% in its Nasdaq debut on August 5^[8].

Attovia is a Phase 1 biopharmaceutical company developing biotherapeutics for immune-mediated diseases, with no approved products or product revenue. The fact that a pre-revenue, Phase 1 biotech could upsize by 45% and trade up nearly 30% on day one is a meaningful signal: the biotech IPO window is open, and demand for clinical-stage paper is robust. Renaissance Capital noted the deal valued Attovia at approximately $731 million market cap at pricing^[8].

Two SPACs also priced in the same window—ARC Group Securities Acquisition I (FJDIU) and BOA Acquisition Corp. II (THEOU)—each at the standard $10 unit price^[9]. These are small deals ($105 million and $125 million respectively), but their presence on the calendar alongside operating-company IPOs and large follow-ons suggests the full-spectrum issuance machine is running.

The Structural Backdrop: Technology Overtakes Liquidity

The supply wave is arriving against a structural backdrop that market participants are still calibrating. JPMorgan’s annual market-structure survey, published July 31, 2026, found that financial market technology has overtaken access to liquidity as traders’ leading concern—the first time in the survey’s history that liquidity did not hold the top spot^[10]. AI, blockchain adoption, and consolidated tape developments are reshaping how firms access liquidity and process information.

Meanwhile, Liquidnet’s Q2 2026 US Liquidity Landscape report found that trading has shifted back toward lit venues, off-exchange behavior is evolving, and macro uncertainty continues to make execution conditions challenging for institutional investors^[6]. The IOSCO Board published a consultation report in May 2026 on the evolution of market liquidity during the trading day, a signal that global regulators are watching intraday liquidity dynamics with heightened attention^[6].

Citadel Securities, in its August 3 market note titled “After the Reset,” described “sharp rotations” and one of the most technically challenging trading environments in recent years^[6]. That note was published before the SpaceX unlock. The interaction between a structurally fragile liquidity environment and a sudden doubling of supply in a single name is precisely the kind of dynamic that can produce disordered price discovery—orderly if absorptive capacity is sufficient, disorderly if it is not.

Lockup Calendar: More Supply Coming

SpaceX is not the only lockup event this month. The Fundrise Innovation Fund (NYSE: VCX) announced on July 24 that it was accelerating its post-listing lockup expiration from September 14 to August 13, 2026, concluding that the lockup period had “achieved its primary purpose of supporting orderly price discovery”^[11]. SPACInsider flagged additional SPAC lockup expirations throughout August^[11].

On the buyback side, Itochu Corporation (8001.T) announced a ¥3,000 billion share buyback program, with ¥150 billion to be acquired via tender offer^[12]—a counterbalancing demand signal, though one that operates in a different market (Tokyo) and at a different scale than the US supply wave. AB InBev also closed books on a secondary offering on August 3^[12], suggesting the global supply theme extends beyond US borders.

What to Watch Next

The immediate indicators to monitor over the coming days and weeks:

• SpaceX trading volume and price reaction: The first sessions after the unlock are the critical test. If the 911 million newly sellable shares are absorbed without a sharp leg lower, it signals deep institutional demand. If the stock breaks below $100—the psychological floor below the $104.83 record low—the short thesis gains momentum and further lockup tranches become more likely to sell.
• SpaceX short interest dynamics: With 35% of the float already short, a squeeze is theoretically possible if unlocked holders do not sell. Conversely, if unlocked holders do sell into an already short-heavy tape, the combination of new supply and existing shorts could produce a cascading effect.
• Follow-on performance: Watch whether PLD, CLS, and TWST stabilize above their offering prices. If they break below deal pricing, it signals the market’s absorptive capacity is exhausted, and the window for further issuance may close.
• The next IPO calendar: The Attovia upsize and 29% first-day pop suggest the biotech window remains open. If the next deals on the calendar price successfully, the primary market is functioning. If deals begin to postpone or price below ranges, the window is narrowing.
• Broad market liquidity metrics: Bid-ask spreads, realized volatility, and dark-pool utilization in the names most exposed to the supply wave will reveal whether the structural fragility Citadel flagged is intensifying or stabilizing.
• SpaceX price-trigger lockups: The $175.50 trigger for additional share releases is far above current levels, meaning further unlocks are unlikely in the near term unless the stock rallies sharply. But if SpaceX recovers toward that threshold, a second wave of supply could arrive.

The base case is that the market absorbs this supply with elevated but manageable volatility—issuance cycles have a long history of being digested without systemic disruption. The tail case is that the combination of a structurally fragile liquidity environment, a record-sized lockup unlock, and $5 billion in simultaneous follow-ons exceeds the market’s near-term capacity, producing disordered price action that forces issuers to pull deals and delays the next IPO pipeline. The truth will be visible in the tape within days.

This article is research commentary, not investment advice. All figures are sourced from publicly available filings, press releases, and market data as of August 6, 2026.